secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001815776-25-000025
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics reports $194M cash as of March 31; holds Commercial Day for LNZ100 launch preparations
--------------------------------------------------------------------------------

- Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.
- Hosting Commercial Day on April 15, 2025, focusing on potential approval and launch of LNZ100.
- Presentation includes commercialization strategies, supply chain readiness, and KOL perspectives.
- Cash figure is preliminary and subject to completion of financial closing procedures.
- No other financial results or guidance were provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/0001815776-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/lenz-20250415.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer